|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Peptide sequence around phosphorylation site of threonine 348 (S-R-T(p)-P-R) derived from Human p90RSK.|
|Storage buffer||PBS, pH 7.4, with 50% glycerol|
|Contains||0.02% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for Western blot is Hela cells; suggested positive control for IHC is human breast carcinoma; suggested positive control for ICC/IF is Hela cells.
The p90 ribosomal S6 kinases (RSKs) comprise a family of serine/threonine kinases that lie at the terminus of the ERK pathway. In humans, the RSK family consists of four isoforms (RSK1 to-4). RSK family members are unusual among serine/threonine kinases in that they contain two distinct kinase domains, both of which are catalytically functional. Theses kinase dimains are activated in a sequential manner by a series of phosphorylations. RSK regulates gene expression via association and phosphorylation of transcriptional regulators including c-Fos, estrogen receptor, NFkappaB/IkappaB alpha, cAMP-response element-binding protein (CREB). ERK activates the C-terminal kinase of RSK, leading to activation of the N-terminal kinase. Members of the RSK family are present in the cytoplasm as well as the nucleus. Addition of growth factor to the cells results in the activation of both cytosolic and nuclear RSK and the translocation of the cytosolic RSK into the nucleus upon activation. The activation and nuclear translocation of RSK result in phosphorylation and activation of transcription factors.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.